Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Realty Income Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Realty Income Corp trades at $63.41 (market cap $59.04B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays a 5.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | O | |
|---|---|---|
Market Cap | $39.89B | $59.04B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $67.56 |
52-Week Low | $278.09 | $55.93 |
Enterprise Value | $38.15B | $88.84B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Realty Income (O) trades at $63.31, up 0.22% on the day, with a bullish technical signal from moving averages and strong support at $63. The company shows robust revenue growth, reaching $5.75B in 2025, and maintains a high gross margin of 92.54%, though it has missed recent EPS estimates. Dividend payments remain consistent at $0.27 monthly, supporting income-focused strategies.
Outlook is cautiously optimistic with a consensus price target of $67.86, offering ~7% upside. Risks include rising debt levels and interest expense, but strategic expansion into data centers and high occupancy rates provide stability. Analyst sentiment is mixed with 41% buy ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
